MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review

医学 系统回顾 临床试验 观察研究 肿瘤科 内科学 梅德林 随机对照试验 肺癌 科克伦图书馆 生物信息学 生物 生物化学
作者
Yiting Dong,Jiachen Xu,Boyang Sun,Jie Wang,Zhijie Wang
出处
期刊:Molecular Diagnosis & Therapy [Adis, Springer Healthcare]
卷期号:26 (2): 203-227 被引量:68
标识
DOI:10.1007/s40291-021-00568-w
摘要

INTRODUCTION: Numerous therapeutic agents specifically targeting the mesenchymal-epithelial transition (MET) oncogene are being developed. OBJECTIVE: The aim of the current review was to systematically identify and analyze clinical trials that have evaluated MET inhibitors in various cancer types and to provide an overview of their clinical outcomes. METHODS: An electronic literature search was carried out in the PubMed and Embase databases to identify published clinical trials related to MET inhibitors. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement was followed for the systematic appraisal of the literature. Data related to clinical outcomes, including progression-free survival, overall survival, objective response rate, and overall tumor response, were extracted. RESULTS: In total, 49 publications were included. Among these, 51.02% were phase II studies, 14.28% were randomized controlled trials, three were phase III studies, two were prospective observational studies, and the remainder were either phase I or Ib studies. The majority (44.89%) of articles reported the clinical outcomes of MET inhibitors, including small molecules, monoclonal antibodies, and other agents, in patients with non-small-cell lung cancer (NSCLC) harboring MET alterations. MET amplification, overexpression, and MET exon 14 skipping mutations were the major MET alteration types reported across the included studies. Clinical responses/outcomes varied considerably. CONCLUSION: This systematic literature review provides an overview of the literature available in Embase and PubMed regarding MET-targeted therapies. MET-selective tyrosine kinase inhibitors (TKIs) (capmatinib, tepotinib, and savolitinib) may become a new standard of care in NSCLC, specifically with MET exon 14 skipping mutations. A combination of MET TKIs with epidermal growth factor receptor (EGFR) TKIs (osimertinib + savolitinib, tepotinib + gefitinib) may be a potential solution for MET-driven EGFR TKI resistance. Further, MET alteration (MET amplification/overexpression) may be an actionable target in gastric cancer and papillary renal cell carcinoma.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wenxin发布了新的文献求助10
刚刚
刚刚
JING完成签到,获得积分10
1秒前
yyyyy发布了新的文献求助30
1秒前
wxbroute完成签到,获得积分10
1秒前
酷酷柚子发布了新的文献求助10
2秒前
2秒前
英姑的应助被勤奋的晋鹏采纳,获得10
2秒前
XY星雨XY完成签到,获得积分10
2秒前
2秒前
2秒前
DW的应助被18859693711采纳,获得10
2秒前
烟花的应助被万荼巳蕊采纳,获得30
2秒前
Donghaol发布了新的文献求助10
2秒前
Hello的应助被若云采纳,获得10
2秒前
月亮完成签到,获得积分10
3秒前
3秒前
3秒前
tianzz完成签到,获得积分10
3秒前
Feiriikt完成签到,获得积分10
4秒前
4秒前
心灵美的大叔完成签到,获得积分10
4秒前
4秒前
余香的应助被绵马紫萁采纳,获得10
5秒前
6秒前
xwx完成签到,获得积分20
6秒前
汉堡包的应助被阿吟采纳,获得10
6秒前
JamesPei的应助被L123采纳,获得10
6秒前
小汪发布了新的文献求助10
6秒前
彭于彦祖的应助被1900采纳,获得30
6秒前
丘比特的应助被寒冷鸭子采纳,获得10
6秒前
李爱国的应助被科研通管家采纳,获得10
6秒前
6秒前
华仔的应助被科研通管家采纳,获得10
6秒前
天天快乐的应助被酷酷柚子采纳,获得10
6秒前
shangguang的应助被科研通管家采纳,获得10
7秒前
丘比特的应助被科研通管家采纳,获得10
7秒前
无极微光的应助被科研通管家采纳,获得20
7秒前
Maroon5发布了新的文献求助10
7秒前
勤奋一一的应助被科研通管家采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181072
求助须知:如何正确求助?哪些是违规求助? 9571092
关于积分的说明 21816478
捐赠科研通 7777477
什么是DOI,文献DOI怎么找? 3433418
关于科研通互助平台的介绍 2557638
邀请新用户注册赠送积分活动 2479460